Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
((Chloroquine OR Hydroxychloroquine) AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
525 results
  • The association between treatment with heparin and survival in patients with Covid-19. [Journal Article]
    J Thromb Thrombolysis. 2020 May 31 [Online ahead of print]Ayerbe L, Risco C, Ayis S
  • This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temper…
  • Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. [Review]
    Clin Rheumatol. 2020 May 30 [Online ahead of print]Soy M, Keser G, … Kayhan S
  • COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current …
  • Risk of using hydroxychloroquine as a treatment of COVID-19. [Journal Article]
    Int J Risk Saf Med. 2020 May 27 [Online ahead of print]Alanagreh L, Alzoughool F, Atoum M
  • The emerging COVID-19 pandemic poses a threat to the global health care system. Given the lack of antiviral therapies or vaccines for the disease, the antimalarial drug hydroxychloroquine (HCQ) obtained much attention as a treatment for COVID-19. However, there are limited and uncertain clinical data to support the beneficial effect of this drug in COVID-19 treatment. HCQ has several side effects…
  • Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. [Journal Article]
    Therapie. 2020 May 23 [Online ahead of print]Roustit M, Guilhaumou R, … French Society of Pharmacology and Therapeutics (SFPT)
  • Chloroquine and hydroxychloroquine are drugs that have shown in vitro activity on the replication of certain coronaviruses. In the context of the SARS-Cov-2 epidemic, the virus responsible for the novel coronavirus disease (COVID-19), these two drugs have been proposed as possible treatments. The results of the first clinical studies evaluating the effect of hydroxychloroquine do not support any …
  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. [Journal Article]
    Lancet. 2020 May 28 [Online ahead of print]Kuderer NM, Choueiri TK, … COVID-19 and Cancer Consortium
  • CONCLUSIONS: Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.
  • Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. [Journal Article]
    J Antimicrob Chemother. 2020 May 30 [Online ahead of print]Lê MP, Peiffer-Smadja N, … C-20–15 DisCoVeRy French Steering Committee
  • Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concent…
  • Registries Offer Insights on COVID-19-Cancer Connection. [Journal Article]
    Cancer Discov. 2020 May 29 [Online ahead of print]
  • Findings from CCC19 and TERAVOLT suggest that patients with cancer may be more likely to die from COVID-19 than people in the general population. Additional mortality risk factors may include age, performance status, treatment with chemotherapy, and exposure to hydroxychloroquine plus azithromycin.
  • COVID-19 in elderly kidney transplant recipients. [Journal Article]
    Am J Transplant. 2020 May 29 [Online ahead of print]Crespo M, José Pérez-Sáez M, … Pascual J
  • The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly the elderly recipients. From March-12th until April-4th 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged ≥65 years old (4.9%). Many of them had had contact with healthcare facilities in the month prior to infection. Median time of symptom onset to admission was 7…
  • Emerging pharmacotherapies for COVID-19. [Review]
    Biomed Pharmacother. 2020 May 14; 128:110267.Salvi R, Patankar P
  • Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 d…
  • Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. [Review]
    Clin Microbiol Infect. 2020 May 26 [Online ahead of print]Rodrigo C, Fernando SD, Rajapakse S
  • CONCLUSIONS: Using HCQ or CQ for HIV/HCV infections is clinically irrelevant now as other effective antivirals are available for viral load suppression (HIV) and cure (HCV). There is no benefit of CQ in dengue and the same conclusion is likely for chikungunya infection. More evidence is needed to confirm if HCQ or CQ is beneficial in COVID-19 infection.
  • Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. [Review]
    Pharmacol Ther. 2020 May 26 [Online ahead of print]Liu T, Luo S, … Shi GP
  • The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2118 on-going clinical trials underway, but to d…
  • A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois. [Journal Article]
    AIDS Patient Care STDS. 2020 May 29 [Online ahead of print]Ridgway JP, Farley B, … McNulty M
  • The risk of COVID-19 among people living with HIV (PLWH) is largely unknown and there have been very few reported cases in the literature. We report a case series of five PLWH with COVID-19. We identified all patients with a diagnosis of HIV who tested positive for SARS-CoV-2 at University of Chicago Medicine between March 1, 2020, and April 7, 2020. We retrospectively collected data regarding de…
New Search Next